Tolgabide

Tolgabide

Clinical data
ATC code	none
Legal status
Legal status	Investigational
Identifiers
IUPAC name 4-{[(E)-(3-Chloro-5-methyl-6-oxocyclohexa-2,4-dien-1-ylidene)(4-chlorophenyl)methyl]amino}butanamide
CAS Number	86914-11-6
PubChem CID	5748792
ChemSpider	14917033
UNII	0L55QF645F
KEGG	D06181
ChEMBL	ChEMBL2104937
Chemical and physical data
Formula	C18H18Cl2N2O2
Molar mass	365.25 g·mol^−1
3D model (JSmol)	Interactive image
SMILES Cc1cc(cc(c1O)/C(=N/CCCC(=O)N)/c2ccc(cc2)Cl)Cl
InChI InChI=1S/C18H18Cl2N2O2/c1-11-9-14(20)10-15(18(11)24)17(22-8-2-3-16(21)23)12-4-6-13(19)7-5-12/h4-7,9-10,24H,2-3,8H2,1H3,(H2,21,23)/b22-17+ Key:AOAFGVWKONLQRN-OQKWZONESA-N

Tolgabide (INN; development code SL-81.0142) is a drug which was patented by Synthélabo as an anticonvulsant but was never marketed.^[1] It is an analogue of progabide and acts similarly to it as a prodrug of GABA, and therefore as an indirect agonist of the GABA receptors.^[1][2]

See also

• Progabide
• Fengabine

References

1. Triggle DJ (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9.
2. "The use of common stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" (PDF). 2002.^{[dead link‍]}